ASTRAZENECA & IBM SIGN GLOBAL STRATEGIC OUTSOURCING AGREEMENT WORTH $1.7 BILLION Thursday 1 February 2001 PDF Print AstraZeneca, one of the world's largest pharmaceuticals companies, and IBM, the world's largest information technology company, today announced that they had signed a global strategic outsourcing agreement worth $1.7 billion over seven years. The agreement, covering the provision of IT infrastructure services to 45 countries, is the largest of its kind in the pharmaceutical industry. Under this agreement, IBM will provide a range of IT services to AstraZeneca throughout its global organisation. These cover PC management, network and communications services, including e-Mail, and computer operations support. AstraZeneca will retain control of its IT technical strategy and the development and support of its application systems. Paul Burfitt, Chief Information Officer of AstraZeneca, said, "Our partnership with IBM will enable AstraZeneca to concentrate the effort of its Information Services (IS) capabilities on such strategic opportunities as e-business and informatics in R&D, and to further encourage added value from IS activities. This partnership will give AstraZeneca access to greater expertise and resource world-wide and will enhance competitive edge. It will also provide additional career and personal development opportunities for IT professionals joining IBM." Frank Kern, General Manager, Professional Services, IBM Global Services, said, "This alliance joins two world class players. Our combined strengths, global reach and culture will enable AstraZenenca to optimise its global IT infrastructure and create business value. IBM will contribute its proven skills and expertise in leveraging technology. This will ensure a robust IT infrastructure to support AstraZeneca's fast moving business, allowing the organisation to focus on strategic IS opportunities." Up to 1200 AstraZeneca staff currently involved in the provision of IT services, principally from the US, UK and Sweden, will transfer to IBM. No redundancies are anticipated. Ref No: 00/021 Notes to the Editor: ABOUT ASTRAZENECA AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $15 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products. ABOUT IBM IBM Global Services is the world's largest information technology services provider, with 2000 revenues of more than $33 billion. Services is the fastest growing part of IBM, with more than 148,000 professionals serving customers in 160 countries. IBM Global Services integrates IBM's broad range of capabilities - services, hardware, software and research to help companies of all sizes realise the full value of information technology. For more information visit http://www.ibm.com/services IBM Life Sciences brings together IBM resources, from research and e-business expertise to data and storage management and high-performance computing, to offer new solutions for the life sciences market, including biotechnology, genomic, e-health, pharmaceutical, and agri-science industries. For further information: Bill Mew IBM Global Services Tel: 44 (0)20 72025769 E-mail: firstname.lastname@example.org Or Emma Thompson / Nicky Morgan On behalf of IBM Tel: 01753 790700 Email: email@example.com firstname.lastname@example.org This press release was distributed by ResponseSource Press Release Wire on behalf of Pleon in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.